Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Provided By GlobeNewswire
Last update: Oct 24, 2025
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed)
– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)
Read more at globenewswire.com
